Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, which is required for the release of acetylcholine at the neuromuscular junction. By blocking this neurotransmitter release, the drug produces a reversible chemical denervation, leading to temporary muscle relaxation and reduced glandular secretion.

The dose of Letybo is individualized and determined by the prescribing clinician based on the specific indication, treated muscle groups, and patient characteristics. No fixed regimen is provided; the prescriber sets the appropriate units and injection sites.

Safety data for Letybo in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk. Breastfeeding mothers should consider the unknown exposure to the infant and discuss alternatives with their healthcare provider.

To order Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Letybo contains the same active protein (botulinum toxin type A) as other licensed products, but differences may exist in formulation, vial size, and manufacturing processes. Clinical efficacy and safety are comparable when used according to approved indications, while specific handling or storage requirements can vary between brands.

Letybo must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If the cold‑chain is interrupted, discard the product to maintain potency and safety.

Letybo is administered by a qualified healthcare professional via intramuscular injection. The prescriber selects the injection sites, dose (in units), and dilution volume according to the therapeutic indication and patient anatomy. Proper aseptic technique and accurate placement are essential for optimal outcomes.

Serious adverse events include dysphagia, respiratory compromise from toxin spread, generalized muscle weakness, severe allergic reactions (including anaphylaxis), urinary retention, and vision changes. Patients should be monitored closely after injection, and any signs of systemic spread require immediate medical attention.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients. Patients with active infections at the proposed injection site, certain neuromuscular disorders such as myasthenia gravis, or those taking medications that markedly increase neuromuscular blockade should avoid use unless a specialist determines it is safe.